ASCO 2021 | Phase I trial of ruxolitinib with radiation and temozolomide in newly diagnosed glioma/glioblastoma

Yasmeen Rauf, MD, Cleveland Clinic, Cleveland, OH, discusses the findings of a Phase I study (NCT03514069) of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma. Radiotherapy plus concomitant and maintenance temozolomide is considered standard treatment in patients with methylated MGMT. The trial aimed to determine the effects of additional ruxolitinib. The first arm of the trial enrolled 25 patients with unmethylated MGMT glioblastoma or grade III glioma and treated them with radiation and ruxolitinib in a standard 3+3 design. Arm 2 enrolled 20 patients with methylated MGMT to receive radiation plus ruxolitinib and temozolomide. Progression-free survival and overall survival findings demonstrated that patients receiving ruxolitinib, radiation and temozolomide did significantly better than those receiving ruxolitinib and radiation alone. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.